...
首页> 外文期刊>Epidemiology and infection >Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population
【24h】

Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population

机译:IL28B和MxA基因多态性对汉族人群HCV清除率的影响

获取原文
           

摘要

The high rate of chronic hepatitis C (CHC) was one of the key issues of global public health concern. Interferon (IFN)-λ relevant genes were in the antiviral treatment pathway, not only influenced hepatitis C virus (HCV) spontaneous clearance, but also affected the IFN-mediated viral clearance. The aim of this study was to identify the association of interleukin 28B (IL28B), myxovirus resistance A (MxA) gene polymorphisms with HCV spontaneous clearance and therapeutic response in Chinese CHC patients. IL28B and MxA gene genotypes were detected among 231 CHC carriers, 428 subjects with HCV spontaneous clearance and 662 CHC patients with pegylated IFN-α and ribavirin (pegIFN-α/RBV) treatment. Patients with MxA rs2071430 TT genotype were more likely to develop HCV infection chronicity (additive model: odds ratio (OR) 1.22, 95% confidence interval (CI) 1.01–1.48, P = 0.042). IL28B rs1298075 variant genotypes (additive model: OR 0.58, 95% CI 0.34–0.98, P = 0.040) and MxA rs17000900 variant genotypes (additive model: OR 0.54, 95% CI 0.30–0.99, P = 0.048) were less likely to achieve a sustained virological response. The life table indicated that patients with IL28B rs1298075 AG genotype were slower to achieve a viral load 500 copies/ml (P = 0.018). During the treatment, the downward trend in viral load was different among each IL28B rs1298075 genotype, especially in subgroup with a baseline HCV-RNA 106 copies/ml (all P 0.05). This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-α/RBV among Chinese CHC patients.
机译:慢性丙型肝炎(CHC)的高发病率是全球公共卫生关注的关键问题之一。干扰素(IFN)-λ相关基因处于抗病毒治疗途径中,不仅影响丙型肝炎病毒(HCV)的自发清除,还影响IFN介导的病毒清除。这项研究的目的是确定白细胞介素28B(IL28B),黏液病毒抗性A(MxA)基因多态性与中国CHC患者的HCV自发清除率和治疗反应之间的关系。在231例CHC携带者,428例HCV自发清除的受试者和662例接受聚乙二醇化IFN-α和利巴韦林(pegIFN-α/ RBV)治疗的CHC患者中检测到IL28B和MxA基因基因型。具有MxA rs2071430 TT基因型的患者更有可能发展HCV感染的慢性病(加性模型:优势比(OR)1.22,95%置信区间(CI)1.01-1.48,P = 0.042)。 IL28B rs1298075变异基因型(加性模型:OR 0.58,95%CI 0.34–0.98,P = 0.040)和MxA rs17000900变异基因型(加性模型:OR 0.54,95%CI 0.30–0.99,P = 0.048)不太可能实现持续的病毒学反应。生命表表明,IL28B rs1298075 AG基因型患者的病毒载量较慢,达到500拷贝/ ml(P = 0.018)。在治疗过程中,每种IL28B rs1298075基因型的病毒载量下降趋势均不同,尤其是在基线HCV-RNA为106拷贝/ ml的亚组中(均P <0.05)。这项研究表明,IL28B rs12980275 AA的转运对中国CHC患者对pegIFN-α/ RBV的治疗反应具有积极作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号